BridgeBio 製藥公司
DE ˙ MUN ˙ US10806X1028
€56.19 ↓ -1.02 (-1.78%)
2026-06-01
分享價格
SecurityDE:2CL / BridgeBio Pharma, Inc.
InstitutionIFP Advisors, Inc
Latest Disclosed Ownership801 shares
Latest Disclosed Value $ 59,482
IFP Advisors, Inc reports 182.04% increase in ownership of 2CL / BridgeBio Pharma, Inc.

On April 13, 2026 - IFP Advisors, Inc filed a 13F-HR form disclosing ownership of 801 shares of BridgeBio Pharma, Inc. (DE:2CL) valued at $50,335 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 284 shares of BridgeBio Pharma, Inc.. This represents a change in shares of 182.04% during the quarter. The current value of the position is $45,008 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-13 2026-03-31 13F BRIDGEBIO PHARMA cs 10806X102 801 517 182.04 59 180.95 0.0012
2026-02-06 2025-12-31 13F BRIDGEBIO PHARMA cs 10806X102 284 -63 -18.16 22 16.67 0.0005
2026-02-06 2025-09-30 13F/A-1 BRIDGEBIO PHARMA cs 10806X102 347 303 688.64 18 1,700.00 0.0005
2025-12-02 2025-09-30 13F BRIDGEBIO PHARMA cs 10806X102 342 298 18 0.0005
2025-07-24 2025-06-30 13F BRIDGEBIO PHARM A cs 10806X102 44 30 214.29 2 0.0001
2025-05-05 2025-03-31 13F BRIDGEBIO PHARMA cs 10806X102 14 0 0.00 0 0.0000
2025-02-04 2024-12-31 13F BRIDGEBIO PHARMA cs 10806X102 14 -1,432 -99.03 0 -100.00 0.0000
2025-02-04 2024-09-30 13F BRIDGEBIO PHARMA cs 10806X102 1,446 -1,637 -53.10 37 -53.85 0.0013
2024-07-30 2024-06-30 13F BRIDGEBIO PHARMA cs 10806X102 3,083 732 31.14 78 8.33 0.0031
2024-07-30 2024-03-31 13F BRIDGEBIO PHARMA cs 10806X102 2,351 1,801 327.45 73 227.27 0.0032
2024-01-09 2023-12-31 13F BRIDGEBIO PHARMA cs 10806X102 550 550 22 0.0010
2023-04-18 2023-03-31 13F BRIDGEBIO PHARMA cs 10806X102 0 -1,000 -100.00 0 0.0000
2023-02-07 2022-12-31 13F BRIDGEBIO PHARMA cs 10806X102 1,000 1,000 0 0.0007
2022-09-06 2022-06-30 13F/A-1 BRIDGEBIO PHARMA INC COM Stock 10806X102 0 -2,405 -100.00 0 -100.00
2022-08-12 2022-06-30 13F BRIDGEBIO PHARMA INC COM Stock 10806X102 0 -2,405 0
2022-08-08 2022-03-31 13F BRIDGEBIO PHARMA INC COM Stock 10806X102 2,405 2,405 66 0.0013
2021-07-13 2021-06-30 13F BRIDGEBIO PHARMA INC COM Stock 10806X102 0 0 0 0.0000
2021-04-30 2021-03-31 13F BRIDGEBIO PHARMA INC COM Stock 10806X102 0 0 0 0.0000
2021-01-25 2020-12-31 13F BRIDGEBIO PHARMA INC COM Stock 10806X102 0 -15 -100.00 0 -100.00
2020-10-29 2020-09-30 13F BRIDGEBIO PHARMA INC COM Stock 10806X102 15 15 1 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.